Nosiheptide Harbors Potent In Vitro and Intracellular Inhbitory Activities against Mycobacterium tuberculosis
文献类型：期刊论文
| 作者 | Yu, Xia; Zhu, Rui; Geng, Zhi ; Kong, Yaoyao; Wang, Fen; Dong, Lingling; Zhao, Liping; Xue, Yi; Ma, Xiaochi; Huang, Hairong
|
| 刊名 | MICROBIOLOGY SPECTRUM
 |
| 出版日期 | 2022 |
| 卷号 | 10期号:65页码:e01444 |
| ISSN号 | 2165-0497 |
| 关键词 | Mycobacterium tuberculosis nosiheptide antimicrobial activity intracellular activity |
| DOI | 10.1128/spectrum.01444-22 |
| 文献子类 | Article |
| 英文摘要 | Multidrug-resistant tuberculosis (MDR-TB) is often associated with poor clinical outcomes. In this study, we evaluated the potential of nosiheptide (NOS) as a new drug candidate for treating Mycobacterium tuberculosis infections, including MDR-TB. The antimicrobial susceptibility testing was performed to determine the MICs of NOS against 18 reference strains of slowly growing mycobacteria (SGM) and 128 clinical isolates of M. tuberculosis. The postantibiotic effects (PAE) and interaction with other antituberculosis drugs of NOS were also evaluated using M. tuberculosis H37Rv. Fifteen out of the 18 tested reference strains of SGM had MICs far below 1 mu g/mL. From the 128 M. tuberculosis clinical isolates, the MIC50 and MIC90 were 0.25 mu g/mL and 1 mu g/mL, respectively; the tentative epidemiological cutoff (ECOFF) was defined at 1 mu g/mL. Furthermore, a Lys89Thr mutation was found in one M. tuberculosis isolate with a MIC of NOS >8 mu g/mL. After 24 h of incubation, NOS at 1 mu g/mL inhibited 25.79 +/- 1.22% of intracellular bacterial growth, which was comparable with the inhibitory rate of 25.71 +/- 3.67% achieved by rifampin at 2 mu g/mL. Compared to rifampicin and isoniazid (INH), NOS had a much longer PAE, i.e., a value of about 16 days. In addition, a partial synergy between NOS and INH was observed. NOS has potent inhibitory activities against M. tuberculosis in vitro as well as in macrophages. Furthermore, the long PAE and partial synergistic effect with INH, in addition to the added safety of long-term use as a feed additive in husbandry, provide support for NOS being a promising drug candidate for tuberculosis treatment. IMPORTANCE This study is aimed at chemotherapy for MDR-TB, mainly to explore the anti-TB activity of the existing chemotherapeutic reagent. We found that NOS has potent inhibitory activities against M. tuberculosis in vitro regardless of the drug-resistant profile. Furthermore, NOS also showed the long PAE and partial synergistic effect with INH and is nontoxic, providing support for its promise as a drug candidate for drug-resistant tuberculosis treatment. This study is aimed at chemotherapy for MDR-TB, mainly to explore the anti-TB activity of the existing chemotherapeutic reagent. We found that NOS has potent inhibitory activities against M. tuberculosis in vitro regardless of the drug-resistant profile. Furthermore, NOS also showed the long PAE and partial synergistic effect with INH and is nontoxic, providing support for its promise as a drug candidate for drug-resistant tuberculosis treatment. |
| 语种 | 英语 |
| WOS记录号 | WOS:000868664700001 |
| 源URL | [http://ir.ihep.ac.cn/handle/311005/299865]  |
| 专题 | 高能物理研究所_多学科研究中心 |
| 作者单位 | 中国科学院高能物理研究所 |
| 推荐引用方式 GB/T 7714 | Yu, Xia,Zhu, Rui,Geng, Zhi,et al. Nosiheptide Harbors Potent In Vitro and Intracellular Inhbitory Activities against Mycobacterium tuberculosis[J]. MICROBIOLOGY SPECTRUM,2022,10(65):e01444. |
| APA | Yu, Xia.,Zhu, Rui.,Geng, Zhi.,Kong, Yaoyao.,Wang, Fen.,...&Huang, Hairong.(2022).Nosiheptide Harbors Potent In Vitro and Intracellular Inhbitory Activities against Mycobacterium tuberculosis.MICROBIOLOGY SPECTRUM,10(65),e01444. |
| MLA | Yu, Xia,et al."Nosiheptide Harbors Potent In Vitro and Intracellular Inhbitory Activities against Mycobacterium tuberculosis".MICROBIOLOGY SPECTRUM 10.65(2022):e01444. |
入库方式： OAI收割
来源：高能物理研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。